Financial Results - Standalone (Quarter Ended June 30, 2026)

  • Revenue from Operations: ₹53,458.78 lakhs (₹534.59 Cr)
  • Other Income: ₹293.13 lakhs (₹2.93 Cr)
  • Total Income: ₹53,751.91 lakhs (₹537.52 Cr)
  • Profit Before Tax: ₹9,622.41 lakhs (₹96.22 Cr)
  • Net Profit: ₹7,130.66 lakhs (₹71.31 Cr)
  • EPS (Basic): ₹7.87
  • EPS (Diluted): ₹7.86
  • Paid-up Equity Share Capital: ₹4,533.99 lakhs (Face Value ₹5 each)

Financial Results - Consolidated (Quarter Ended June 30, 2026)

  • Revenue from Operations: ₹53,579.69 lakhs (₹535.80 Cr)
  • Other Income: ₹45.27 lakhs (₹0.45 Cr)
  • Total Income: ₹53,624.96 lakhs (₹536.25 Cr)
  • Profit Before Tax: ₹10,106.02 lakhs (₹101.06 Cr)
  • Net Profit: ₹7,614.27 lakhs (₹76.14 Cr)
  • EPS (Basic): ₹8.40
  • EPS (Diluted): ₹8.39

Management Changes

  • Shri Rashesh C. Gogri (DIN: 00066291): Change in designation from Non-Executive Director to Managing Director, effective October 1, 2026, subject to shareholder approval at ensuing AGM
  • Smt. Hetal Gogri Gala (DIN: 00005499): Change in designation from Managing Director to Executive Director, effective October 1, 2026, subject to shareholder approval at ensuing AGM
  • Both individuals are related to each other as per disclosure

Committee Reconstitution

Effective October 1, 2026:

  • Audit Committee: Chairman - Shri Bhavesh Vora; Members - Shri Vinay Nayak, Shri Vilas Gaikar, Smt. Jeenal Savla, Shri Narendra Salvi, Shri Rashesh C Gogri
  • CSR Committee: Chairperson - Smt. Hetal Gogri Gala; Members - Shri Pradeep Thakur, Smt. Jeenal Savla, Shri Vilas Gaikar

Effective Immediately:

  • Stakeholders Relationship Committee: Chairman - Shri Parimal Desai; Members - Shri Narendra Salvi, Shri Bhavesh Vora, Shri Rupal Vora

Capacity Expansion

  • Project: Development of Intermediate Block
  • Capacity Addition: 405 KL
  • Investment Required: ₹149 Crores
  • Implementation Period: 1 year
  • Mode of Financing: Internal accruals & Borrowings
  • Rationale: Capacity expansion to serve intermediate & CDMO customers

Audit and Review Details

  • Financial results reviewed by Audit Committee and approved by Board on August 7, 2026
  • Limited review conducted by Gokhale & Sathe Chartered Accountants (Firm Reg. No.: 103264W)
  • Emphasis of Matter: Restatement of Q1 FY26 figures to recognize fair value loss of ₹463.74 lakhs on foreign exchange derivative contract
  • Previous quarter figures restated: Q1 FY25 PAT reduced from ₹512.21 lakhs to ₹477.51 lakhs; EPS reduced from ₹5.65 to ₹5.27

Additional Information

  • Board meeting duration: 2:00 PM to 6:00 PM
  • Information available on company website: www.aartipharmalabs.com
  • Financial results also available on BSE (www.bseindia.com) and NSE (www.nseindia.com) websites